ATXN2 and amyotrophic lateral sclerosis: Finally, we present two separate cohort studies where we identified an intermediate or full-length ATXN2 expansion in 2.2% of all ALS patients across both cohorts; the association was particularly marked for full-length expansions (OR = 6.5).